Floatz logo

HUMAN INTERLEUKIN 2 (IL2, T-CELL GROWTH FACTOR, TCGF) (2-133) VARIANT (A1 DELETED, PRO65>LYS, CYS125>SER), NON-GLYCOSYLATED, PRODUCED IN ESCHERICHIA COLI, CONJUGATED AT N6 OF K65 WITH A PEG DERIVATIVE (30KDA)

Diffuse Large B-cell Lymphoma

Sanofiprotein_peptidePhase 2Active
D
31/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
16/ 100
Competitive Position
73/ 100

Competitive context

270 Active assets in the Diffuse Large B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

HUMAN INTERLEUKIN 2 (IL2, T-CELL GROWTH FACTOR, TCGF) (2-133) VARIANT (A1 DELETED, PRO65>LYS, CYS125>SER), NON-GLYCOSYLATED, PRODUCED IN ESCHERICHIA COLI, CONJUGATED AT N6 OF K65 WITH A PEG DERIVATIVE (30KDA) is also rated in:

esophageal squamous cell carcinomaDormant
C
Indicative ·
33 / 100
View asset →
gastric cancerDormant
C
Indicative ·
33 / 100
View asset →
hepatocellular carcinomaDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →